Published in Ophthalmology on March 17, 2012
Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One (2013) 1.23
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev (2014) 1.09
Subclinical macular findings in infants screened for retinopathy of prematurity with spectral-domain optical coherence tomography. Ophthalmology (2013) 1.07
Inflammation in retinal vein occlusion. Int J Inflam (2013) 0.98
A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion. PLoS One (2013) 0.91
The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open (2014) 0.89
Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol (2013) 0.88
Treatments for macular oedema following central retinal vein occlusion: systematic review. BMJ Open (2014) 0.87
Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion. Int J Ophthalmol (2016) 0.82
The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. J Ophthalmol (2014) 0.82
[Retinal vein occlusion: Therapy of retinal vein occlusion]. Ophthalmologe (2015) 0.79
Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion. Clin Ophthalmol (2014) 0.78
Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis. BMJ Open (2014) 0.76
Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion. Int J Ophthalmol (2012) 0.76
Central Retinal Vein Occlusion: A Review of Current Evidence-based Treatment Options. Middle East Afr J Ophthalmol (2016) 0.75
Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up (BERVOLT study: bevacizumab for RVO long-term follow-up). Graefes Arch Clin Exp Ophthalmol (2015) 0.75
Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial. Electron Physician (2017) 0.75
Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am (2005) 2.24
Choroidal biopsies for intraocular tumors of indeterminate origin. Am J Ophthalmol (2005) 1.87
Photochemical damage of the retina. Surv Ophthalmol (2006) 1.83
Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology (2012) 1.78
Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol (2011) 1.78
Ligneous conjunctivitis. Surv Ophthalmol (2003) 1.59
Biomechanical regulation of blood vessel growth during tissue vascularization. Nat Med (2009) 1.58
Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes Dev (2007) 1.49
Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand (2006) 1.47
Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci (2002) 1.33
Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology (2005) 1.32
Sunlight exposure and pathogenesis of uveal melanoma. Surv Ophthalmol (2004) 1.20
Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients. Blood (2006) 1.20
Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest Ophthalmol Vis Sci (2003) 1.14
The cut-and-paste method for primary pterygium surgery: long-term follow-up. Acta Ophthalmol Scand (2005) 1.12
Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care (2008) 1.10
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res (2006) 1.09
Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci (2013) 1.08
Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci (2002) 1.08
Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Invest Ophthalmol Vis Sci (2008) 0.99
Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer (2010) 0.98
A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol (2007) 0.96
Expression and prognostic significance of iNOS in uveal melanoma. Int J Cancer (2010) 0.96
Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res (2005) 0.95
c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Invest Ophthalmol Vis Sci (2004) 0.95
Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci U S A (2012) 0.94
Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol Scand (2002) 0.93
Uveal melanoma: a study on incidence of additional cancers in the Swedish population. Invest Ophthalmol Vis Sci (2006) 0.92
Oncocytoma of the lacrimal gland. Acta Ophthalmol Scand (2007) 0.91
Intraoperative mitomycin C versus autologous conjunctival autograft in surgery of primary pterygium with four-year follow-up. Acta Ophthalmol (2010) 0.91
Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo. FASEB J (2007) 0.90
To biopsy or not to biopsy? Acta Ophthalmol (2009) 0.90
Structure and function of the N-cadherin/catenin complex in retinoblastoma. Invest Ophthalmol Vis Sci (2002) 0.89
Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci (2005) 0.89
Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci (2008) 0.89
The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden. J Diabetes Complications (2010) 0.88
Subthreshold transpupillary thermotherapy reduces experimental choroidal neovascularization in the mouse without collateral damage to the neural retina. Invest Ophthalmol Vis Sci (2004) 0.88
Fine-needle aspiration cytology and immunocytochemistry of orbital masses. Diagn Cytopathol (2006) 0.88
A prospective study of children treated for retinoblastoma: cognitive and visual outcomes in relation to treatment. Acta Ophthalmol Scand (2002) 0.88
Topical chemotherapy for ocular surface squamous neoplasia: current status. Br J Ophthalmol (2009) 0.87
Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci (2003) 0.86
Mantle cell lymphoma of the iris. Acta Ophthalmol Scand (2007) 0.86
Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Acta Ophthalmol (2008) 0.85
Photodynamic therapy of experimental choroidal neovascularization in the mouse. Curr Eye Res (2006) 0.84
Photodynamic therapy for circumscribed choroidal haemangioma. Acta Ophthalmol Scand (2002) 0.83
Transpupillary thermotherapy of predominantly occult choroidal neovascularization in age-related macular degeneration with 12 months follow-up. Acta Ophthalmol Scand (2003) 0.83
JARID1B protein expression and prognostic implications in uveal melanoma. Invest Ophthalmol Vis Sci (2012) 0.82
Nuclear HER3 is associated with favorable overall survival in uveal melanoma. Int J Cancer (2011) 0.82
Retinoblastoma: direct chemotherapeutic drug delivery into the vitreous cavity. Br J Ophthalmol (2012) 0.80
In Vivo Imaging of Subretinal Bleb-Induced Outer Retinal Degeneration in the Rabbit. Invest Ophthalmol Vis Sci (2015) 0.80
Malignant solitary fibrous tumour of the orbit. Acta Ophthalmol (2008) 0.80
Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study. Br J Ophthalmol (2012) 0.79
Vision-related function after low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. Acta Ophthalmol (2010) 0.79
Retinal vascular development and pathologic retinal angiogenesis are not impaired in matrix metalloproteinase-2 deficient mice. Curr Eye Res (2005) 0.79
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Acta Ophthalmol (2008) 0.79
[Not Available]. Duodecim (2007) 0.79
Photoreceptor survival in transplantation of autologous iris pigment epithelial cells to the subretinal space. Acta Ophthalmol Scand (2002) 0.79
Carcinoid presenting as extrinsic eye muscle metastasis. Acta Ophthalmol (2009) 0.78
Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Acta Ophthalmol (2008) 0.78
Delayed neovascularization in inflammation-induced corneal neovascularization in interleukin-10-deficient mice. Acta Ophthalmol (2008) 0.78
Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ). Acta Ophthalmol (2010) 0.78
TIMP-3 mRNA is not overexpressed in Sorsby fundus dystrophy. Am J Ophthalmol (2003) 0.78
Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. Eur J Ophthalmol (2011) 0.77
Involvement of purinergic P2 receptors in experimental retinal neovascularization. Curr Eye Res (2008) 0.77
Macular structure and function and the development of retinopathy in diabetes. Clin Exp Optom (2011) 0.77
Safety of irrigation with 5-fluorouracil in a sealed-capsule irrigation device in the rabbit eye. J Cataract Refract Surg (2007) 0.77
Uveitis masquerade syndromes: diffuse retinoblastoma in an older child. Acta Ophthalmol Scand (2007) 0.77
Primary transpupillary thermotherapy of "small" choroidal melanoma: is it safe? Br J Ophthalmol (2008) 0.77
Neovascular age-related macular degeneration: too many theories, too little knowledge? Acta Ophthalmol (2008) 0.77
Drusen maculopathy: a risk factor for AMD. Can we prevent visual loss? Acta Ophthalmol Scand (2003) 0.76
Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Acta Ophthalmol (2008) 0.76
Optical Coherence Tomography Angiography in Central Retinal Vein Occlusion: Correlation Between the Foveal Avascular Zone and Visual Acuity. Invest Ophthalmol Vis Sci (2016) 0.75
Shall we use Avastin or Lucentis for ocular neovascularization? Acta Ophthalmol (2008) 0.75
Who's the faster runner: the cheetah or the rabbit? Acta Ophthalmol (2009) 0.75
New treatments for neovascular age-related macular degeneration: when should we use them? Acta Ophthalmol Scand (2007) 0.75